We are entering an era of systemic organ protection
Two subcutaneous fixed-ratio combinations of basal insulin and GLP-1 RA are currently available for once-daily administration: insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (IGlarLixi) [5]
So you're, you're definitely doing, I always do this personalized medicine approach and we try to find the right thing, but most drugs, I would say are, are maybe in the 60% effectiveness category
That includes the exact bulk substance and form, whether an applicable USP/NF monograph or approved-drug-component route exists, whether the substance is formally listed, whether an FDA interim enforcement policy applies, state law, prescription requirements, sourcing, formulation, and other standards
Regular monitoring through diabetes reviews, including HbA1c measurements, renal function tests, liver function tests (where indicated), and assessment of treatment response, ensures optimal safety and efficacy
While research is still ongoing, one popular hypothesis is that GLP-1 agonists cause weight loss primarily because patients who are less hungry eat fewer calories consistently
